Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma.

Background Sunitinib is an approved treatment for metastatic renal cell carcinoma (mRCC). The safety profile and efficacy of sunitinib were confirmed in a global expanded access trial (ClinicalTrials.gov identifier: {"type":"clinical-trial","attrs":{"text":"NCT00130897","term_id":"NCT00130897"}}NCT00130897). This report presents a subanalysis of the final trial data from patients in Latin America.